European Psychiatry
June 1, 2026
R. Pionke-Ubych, J. Piwińska, L. Gaweda
Introduction Previous studies have shown that self-disturbances mediate the relationship between traumatic life events and psychotic-like experiences. However, it is unknown whether this model may be extended to stress sensitivity. We hypothesize that a history of early trauma increases the risk for psychotic experiences through stress sensitization and disturbance of the basic sense of self....
European Psychiatry
June 1, 2026
J. Chapelas, L. Costa, M. Alves et al.
Introduction The expanding use of cannabis, in both recreational and medicinal contexts, highlights a dual reality of therapeutic potential and clinical concern. On one side, cannabinoids show promising medical applications, including chronic pain relief and antiemetic effects. On the other, cannabis consumption is linked to a broad spectrum of adverse outcomes. Psychiatric effects range from...
European Psychiatry
June 1, 2026
S. Joowong, P. Tansupasiri
Introduction Following Thailand’s cannabis decriminalization in 2022, a marked rise in psychiatric presentations related to cannabis use has been observed nationwide. While international evidence has linked high-THC cannabis exposure to psychosis and substance-induced disorders, empirical data from Asian settings remain limited. This late-breaking study provides updated national trends and...
European Psychiatry
June 1, 2026
V. Casati, Kevin la Monica, Mauro Angeletti et al.
Introduction Intranasal esketamine has emerged as an innovative treatment for TRD due to its rapid antidepressant effects. However, the clinical response is heterogeneous, and growing evidence suggests that comorbid personality disorders (PDs) may significantly shape treatment outcomes. Although PDs are frequently diagnosed in TRD patients, little is known about their differential influence on...
European Psychiatry
June 1, 2026
A. K. Sikora
Abstract Catatonia is a potentially life-threatening psychomotor syndrome that can complicate substance intoxication and may be missed in acute psychiatric and addiction settings. Synthetic cannabinoids (e.g., Spice/K2) are associated with severe neuropsychiatric presentations including agitation, psychosis, autonomic instability, and diagnostic ambiguity. This talk presents a clinical case of...
New Psychoactive Substances
June 1, 2026
Philippe Pfeifer, Katharina Elisabeth Grafinger
Abstract Synthetic cannabinoid receptor agonists (SCRAs), originally developed for biomedical research purposes, are now one of the biggest classes of new psychoactive substances (NPS). Due to their higher binding affinity and activity to the cannabinoid receptors, compared to Δ9-THC, they pose a higher pharmacological and toxicological risk for consumers. Different intoxication symptoms (e.g.,...
European Psychiatry
June 1, 2026
Ágnes Zinner-Gérecz, X. Gonda, Szilvia Kresznerits
Introduction Endometriosis is a chronic, systemic, estrogen-dependent gynecological disorder affecting approximately 10% of women of reproductive age. Beyond the hallmark physical symptoms, the condition is associated with significant psychological burden. The disease not only generates local inflammation but also affects central pain modulation and gene expression in brain regions responsible...
Psychiatry Research
June 1, 2026
Petru Ifteni, A. Miron, R.M. Necula et al.
INTRODUCTION Drug use in Europe has increased in recent years, including a marked rise in new psychoactive substances (NPS). Substance use disorders negatively affect physical and mental health. Psychotic disorders are highly prevalent among drug users. Establishing a link between illicit drug use and schizophrenia would help clarify the progression risk after substance-induced psychosis. AIMS...
European Psychiatry
June 1, 2026
N. Aguayo-Verdugo, N. Ulloa-Chamblás, R. Zúñiga-Tapia et al.
Introduction University students, particularly in health-related fields, face rising levels of stress, anxiety, and depression, which negatively affect academic performance, social engagement, and overall well-being. Post-pandemic challenges, such as social isolation, uncertainty, and abrupt transitions to online learning, have exacerbated these issues. Mindfulness-based interventions (MBIs)...
European Psychiatry
June 1, 2026
J. B. French, J. Kar, B. R. Carr
Introduction The psychiatric incorporation of mindfulness has advanced without a parallel precision in definition. Within both clinical and lay discourse, mindfulness is often conflated with meditation broadly, or with forms of contemplation oriented toward ethical or spiritual ends. This conceptual slippage obscures distinct phenomenological structures and risks importing unexamined...